Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 12Unknown 6Terminated 4Recruiting 3Active not recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 18Other solid neoplasm 18Gynecologic 4Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Lymphoid 1Endocrine 1

Conditions

Breast Neoplasms 849Triple Negative Breast Neoplasms 136Ovarian Neoplasms 55Colorectal Neoplasms 49Carcinoma, Non-Small-Cell Lung 47Neoplasms 43Neoplasm Metastasis 43Prostatic Neoplasms 42Lung Neoplasms 38Melanoma 30Carcinoma, Intraductal, Noninfiltrating 29Uterine Cervical Neoplasms 27Pancreatic Neoplasms 25Colonic Neoplasms 25Stomach Neoplasms 23Squamous Cell Carcinoma of Head and Neck 23Endometrial Neoplasms 23Carcinoma, Renal Cell 23Breast Carcinoma In Situ 22Esophageal Neoplasms 17Urinary Bladder Neoplasms 16Motor Activity 16Inflammatory Breast Neoplasms 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 14Breast Cancer Female 13Brain Neoplasms 12Anatomic Stage I Breast Cancer AJCC v8 12Gastrointestinal Neoplasms 11

Interventions

fludarabine 1Platinum 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1BAY 1895344 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Mesothelioma, Malignant × Breast × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡